Skip to main content

Capmatinib Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 30, 2023.

Applies to capmatinib: oral tablet.

Serious side effects of Capmatinib

Along with its needed effects, capmatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking capmatinib:

More common

Less common

Incidence not known

Other side effects of Capmatinib

Some side effects of capmatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to capmatinib: oral tablet.


Very common (10% or more): Lymphocytes decreased (44%), hemoglobin decreased (24%), leukocytes decreased (23%)[Ref]


Very common (10% or more): Noncardiac chest pain (e.g., chest discomfort, musculoskeletal chest pain, noncardiac chest pain, chest pain) (15%), back pain (14%)[Ref]


Very common (10% or more): Albumin decreased (68%), creatinine increased (62%), alanine aminotransferase increased (37%), alkaline phosphatase increased (32%), amylase increased (31%), gamma-glutamyltransferase increased (29%), lipase increased (26%), aspartate aminotransferase increased (25%), sodium decreased (23%), phosphate decreased (23%), glucose decreased (21%), weight loss (10%)[Ref]


Very common (10% or more): Dyspnea (24%), cough (16%)

Common (1% to 10%): ILD/pneumonitis[Ref]


Very common (10% or more): Peripheral edema (e.g., peripheral swelling, peripheral edema, fluid overload) (52%), fatigue/asthenia (32%), pyrexia/increased body temperature (14%)[Ref]


Very common (10% or more):

Common (1% to 10%): Acute kidney injury (including renal failure)[Ref]


Common (1% to 10%): Pruritus (allergic and generalized), cellulitis, urticaria[Ref]


Very common (10% or more): Nausea (44%), vomiting (28%), constipation (18%), diarrhea (18%)

Common (1% to 10%): Acute pancreatitis[Ref]

Frequently asked questions


1. Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.